GlassScriptPhysician profile
Janelle Ashmore
NPI 1710604418
$10,106.71
in general payments reported to CMS, 2019-2025
38 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.12 · 2023: $2,469 · 2024: $5,836 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,204 · Consulting Fee: $944 · Travel and Lodging: $368 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,430.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,204.00 |
| Consulting Fee | $943.88 |
| Travel and Lodging | $367.59 |
| Education | $119.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,612.62 | 2024 | |
| Immunogen, INC. | $1,335.83 | 2023-2024 | Elahere, Elahere |
| Daiichi Sankyo INC. | $863.59 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Genmab U.S., INC. | $371.92 | 2023-2025 | Tivdak |
| Glaxosmithkline, LLC. | $313.18 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $291.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $274.70 | 2022-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $272.62 | 2023-2025 | Keytruda, Lenvima |
| Myriad Genetic Laboratories, INC. | $268.36 | 2023-2025 | Precisetumor |
| Spectrum Pharmaceuticals INC. | $230.72 | 2023-2025 | Rolvedon |
| Seagen INC. | $138.41 | 2022-2025 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $103.58 | 2023-2025 | |
| Pfizer INC. | $96.33 | 2024-2025 | |
| Tempus Ai, INC | $95.41 | 2024 | |
| Incyte Corporation | $76.97 | 2024-2025 | Jakafi, Monjuvi |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Ashmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.